• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【分子编号】32438

【品名】(3S,4E)-3-[[tert-butyl(dimethyl)silyl]oxy]-5-iodo-4-methyl-4-pentenal

【CA登记号】

【 分 子 式 】C12H23IO2Si

【 分 子 量 】354.30339

【元素组成】C 40.68% H 6.54% I 35.82% O 9.03% Si 7.93%

与该中间体有关的原料药合成路线共 3 条

合成路线1

该中间体在本合成路线中的序号:(XXVI)

The reaction of 5-iodo-4-methyl-3-(tert-butydimethylsilyloxy)-4-pentenal (XXVI) with methyl iodide and CrCl2 in dioxane/THF gives the diiodohexenal (XXVII), which is desilylated with TBAF in THF yielding the secondary alcohol (XXVIII). The esterification of (XXVIII) with protected perhydropyridazinecarboxylic acid (XXIX) by means of EDC and DIEA in dichloromethane affords the carboxylic ester (XXX), which is deprotected with TFA in dichloromethane to give the unprotected ester (XXXI). The condensation of (XXXI) with carboxylic acid (XXXII) by means of 1-hydroxy-7-azabenzotriazole (HOAt) and EDC in dichloromethane yields the protected amide (XXXIII), which is deprotected with TFA affording (XXXIV) with a free amino group. The condensation of (XXXIV) with the acid (XXXV) (obtained by oxidation of carbinol (XXXVI) with tetrapropylammonium perruthenate (TPAP)) by means of O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) and DIEA in DMF provides the amide (XXXVII), which is cyclized by means of triphenylarsine and Pd dibenzylideneacetone complex yielding the cyclic intermediate (XXXVIII).

1 Nicolaou, K.C.; et al.; Total synthesis of sanglifehrin A. Angew Chem. Int Ed Engl 1999, 38, 16, 2447.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XXVI) 32438 (3S,4E)-3-[[tert-butyl(dimethyl)silyl]oxy]-5-iodo-4-methyl-4-pentenal C12H23IO2Si 详情 详情
(XXVII) 32439 tert-butyl([(1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl]oxy)dimethylsilane; tert-butyl(dimethyl)silyl (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl ether C13H24I2OSi 详情 详情
(XXVIII) 32440 (1E,3S,5E)-1,6-diiodo-2-methyl-1,5-hexadien-3-ol C7H10I2O 详情 详情
(XXIX) 32441 (3S)-1,2-bis(tert-butoxycarbonyl)hexahydro-3-pyridazinecarboxylic acid C15H26N2O6 详情 详情
(XXX) 32442 1,2-di(tert-butyl) 3-[(1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl] (3S)tetrahydro-1,2,3-pyridazinetricarboxylate C22H34I2N2O6 详情 详情
(XXXI) 32443 (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl (3S)hexahydro-3-pyridazinecarboxylate C12H18I2N2O2 详情 详情
(XXXII) 32444 (2S)-2-([(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutanoyl]amino)-3-(3-hydroxyphenyl)propionic acid C19H28N2O6 详情 详情
(XXXIII) 32445 (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl (3S)-1-[(2S)-2-([(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutanoyl]amino)-3-(3-hydroxyphenyl)propanoyl]hexahydro-3-pyridazinecarboxylate C31H44I2N4O7 详情 详情
(XXXIV) 32446 (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl (3S)-1-[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-(3-hydroxyphenyl)propanoyl]hexahydro-3-pyridazinecarboxylate C26H36I2N4O5 详情 详情
(XXXV) 32447 (3R,4S,5R,6R)-1,4-dimethyl-3-[(E)-2-(tributylstannyl)ethenyl]-2,9-dioxabicyclo[3.3.1]nonane-6-carboxylic acid C24H44O4Sn 详情 详情
(XXXVI) 32448 [(3R,4S,5S,6S)-1,4-dimethyl-3-[(E)-2-(tributylstannyl)ethenyl]-2,9-dioxabicyclo[3.3.1]non-6-yl]methanol C24H46O3Sn 详情 详情
(XXXVII) 32449 (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl (3S)-1-[(2S)-2-([(2S)-2-[([(3R,4S,5R,6R)-1,4-dimethyl-3-[(E)-2-(tributylstannyl)ethenyl]-2,9-dioxabicyclo[3.3.1]non-6-yl]carbonyl)amino]-3-methylbutanoyl]amino)-3-(3-hydroxyphenyl)propanoyl]hexahydro-3-pyridazinecarboxylate; (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl (3S)-1-[(2S)-2-([(2S)-2-[([(3R,4S,5R,6R)-1,4-dimethyl-3-[(E)-2-(tributylstannyl)ethenyl]-2,9-dioxabicyclo[3.3.1]non-6-yl]carbonyl)amino]-3-methylbutanoyl]amino)-3-(3-hydroxyphenyl)propanoyl]hexahydro-3-pyridazinecarboxylate C50H78I2N4O8Sn 详情 详情
(XXXVIII) 32450 (4R,7S,10S,16S,19S,25S,26R,27R)-10-(3-hydroxybenzyl)-19-[(E)-2-iodo-1-methylethenyl]-7-isopropyl-1,26-dimethyl-18,28,29-trioxa-6,9,12,30-tetraazatetracyclo[23.3.1.1(12,16).0(4,27)]triaconta-21,23-diene-5,8,11,17-tetrone; (4R,7S,10S,16S,19S,25S,26R,27R)-10-(3-hydroxybenzyl)-19-[(E)-2-iodo-1-methylethenyl]-7-isopropyl-1,26-dimethyl-18,28,29-trioxa-6,9,12,30-tetraazatetracyclo[23.3.1.1(12,16).0(4,27)]triaconta-21,23-diene-5,8,11,17-tetrone C38H51IN4O8 详情 详情

合成路线2

该中间体在本合成路线中的序号:(XLIV)

The condensation of 3-hydroxybenzaldehyde (XXXIV) with phosphonate (XXXV) by means of DBU in dichloromethane gives the propenoic ester (XXXVI), which is enanthioselectively reduced catalyzed by (+)-1,2-bis((2S,5S)-2,5-diethylphospholano)benzene(1,5-cyclooctadiene)rhodium (I) trifluoromethanesulfonate ((S,S)-DuP-Rh+OTf-) yielding the L-phenylalanine derivative (XXXVII). The deprotection of (XXXVII) by hydrogenation as usual affords the free amino acid (XXXVIII), which is condensed with Boc-L-valine (XXXIX) by means of EDC and HOAt to afford the dipeptide (XL). Hydrolysis of the ester group of (XXXIX) with LiOH in THF/water affords the N-protected amino acid (XLI), which is condensed with the perhydropyridazine (XLII) by means of EDC and HOAt to give the protected intermediate (XLIII). Finally, this compound is deprotected with TFA in dichloromethane to afford the desired intermediate the bis(iodovinyl) compound (XXXI). The intermediate perhydropyridazine (XLII) has been obtained as follows: The reaction of the iodoaldehyde (XLIV) with iodoform and CrCl2 in dioxane/THF gives the 1,6-diiodohexadiene (XLV), which, previous desilylation with TBAF, is condensed with the protected hexahydropyridazinecarboxylic acid (XLVI) by means of EDC, 4-Ppy and DIEA in dichloromethane to provide the protected diiodo ester (XLVII). Finally, this compound is deprotected with TFA in dichloromethane to yield the desired intermediate the perhydropyridazine (XLII).

1 Nicolaou, K.C.; et al.; Total synthesis of the novel immunosuppressant Sanglifehrin A. J Am Chem Soc 2000, 122, 16, 3830.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XXXI) 32446 (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl (3S)-1-[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-(3-hydroxyphenyl)propanoyl]hexahydro-3-pyridazinecarboxylate C26H36I2N4O5 详情 详情
(XXXIV) 28537 3-hydroxybenzaldehyde 100-83-4 C7H6O2 详情 详情
(XXXV) 35887 methyl 2-[[(benzyloxy)carbonyl]amino]-2-(diethoxyphosphoryl)acetate C15H22NO7P 详情 详情
(XXXVI) 35888 methyl (E)-2-[[(benzyloxy)carbonyl]amino]-3-(3-hydroxyphenyl)-2-propenoate C18H17NO5 详情 详情
(XXXVII) 35889 methyl (2S)-2-[[(benzyloxy)carbonyl]amino]-3-(3-hydroxyphenyl)propanoate C18H19NO5 详情 详情
(XXXVIII) 35890 methyl (2S)-2-amino-3-(3-hydroxyphenyl)propanoate C10H13NO3 详情 详情
(XXXIX) 19733 (2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutyric acid C10H19NO4 详情 详情
(XL) 35891 methyl (2S)-2-([(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutanoyl]amino)-3-(3-hydroxyphenyl)propanoate C20H30N2O6 详情 详情
(XLI) 32444 (2S)-2-([(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutanoyl]amino)-3-(3-hydroxyphenyl)propionic acid C19H28N2O6 详情 详情
(XLII) 32443 (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl (3S)hexahydro-3-pyridazinecarboxylate C12H18I2N2O2 详情 详情
(XLIII) 32445 (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl (3S)-1-[(2S)-2-([(2S)-2-[(tert-butoxycarbonyl)amino]-3-methylbutanoyl]amino)-3-(3-hydroxyphenyl)propanoyl]hexahydro-3-pyridazinecarboxylate C31H44I2N4O7 详情 详情
(XLIV) 32438 (3S,4E)-3-[[tert-butyl(dimethyl)silyl]oxy]-5-iodo-4-methyl-4-pentenal C12H23IO2Si 详情 详情
(XLV) 32439 tert-butyl([(1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl]oxy)dimethylsilane; tert-butyl(dimethyl)silyl (1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl ether C13H24I2OSi 详情 详情
(XLVI) 32441 (3S)-1,2-bis(tert-butoxycarbonyl)hexahydro-3-pyridazinecarboxylic acid C15H26N2O6 详情 详情
(XLVII) 32442 1,2-di(tert-butyl) 3-[(1S,3E)-4-iodo-1-[(E)-2-iodo-1-methylethenyl]-3-butenyl] (3S)tetrahydro-1,2,3-pyridazinetricarboxylate C22H34I2N2O6 详情 详情

合成路线3

该中间体在本合成路线中的序号:(XXV)

Chiral tetracyclic macrolactone (XXXVI): The condensation of the chiral aldehyde (XXV) with phosphonate (XXVI) in the usual way gives the nonatrienoic ester (XXVII), which is reduced with DIBAL to the corresponding alcohol and oxidized with MnO2 to the carbaldehyde (XXVIII). The condensation of (XXVIII) with the chiral oxazolidinone intermediate (VI) through its boron enolate yields the expected adduct (XXIX), which is reduced with Me4NBH(OAc)3 to afford the dihydroxy compound (XXX). The dethioacetalization of (XXX) by means of PhI(OCOCF3)2 in dichloromethane provides the cyclic ketal (XXXI). The regiocontrolled reduction of (XXXI) by means of NaBH4 in THF/water cleaves the chiral auxiliary to yield the carbinol (XXXII), which is successively oxidized with DMP and NaClO2 to afford the carboxylic acid (XXXIII) (1). The condensation of (XXXIII) with the chiral tripeptide intermediate (XV) by means of TBAF, HATU and DIEA in acetonitrile provides the corresponding amide (XXXIV), which is submitted to macrocyclization by means of LiOH, EDC and DIEA in dichloromethane to give the polycyclic macrolactone (XXXV). Finally, the Boc protecting group of (XXXV) is removed by means of Tms-OTf and lutidine in dichloromethane to afford the target chiral tetracyclic macrolactone (XXXVI)

1 Duan, M.S.; Paquette, L.A.; Enantioselective total synthesis of the cyclophilin-binding immunosuppressive agent sanglifehrin A. Angew Chem. Int Ed 2001, 40, 19, 3632.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(VI) 60104 (2R)-1-[(4S)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-2-[2-(2-methyl-1,3-dithian-2-yl)ethyl]-1,3-pentanedione C22H29NO4S2 详情 详情
(XV) 60112 methyl (3S)-1-((2S)-2-{[(2S)-2-amino-3-methylbutanoyl]amino}-3-{3-[(tert-butoxycarbonyl)oxy]phenyl}propanoyl)hexahydro-3-pyridazinecarboxylate C25H38N4O7 详情 详情
(XXV) 32438 (3S,4E)-3-[[tert-butyl(dimethyl)silyl]oxy]-5-iodo-4-methyl-4-pentenal C12H23IO2Si 详情 详情
(XXVI) 60121 methyl (E)-4-(dipropoxyphosphoryl)-2-butenoate C11H21O5P 详情 详情
(XXVII) 60122 methyl (2E,4E,7S,8E)-7-{[tert-butyl(dimethyl)silyl]oxy}-9-iodo-8-methyl-2,4,8-nonatrienoate C17H29IO3Si 详情 详情
(XXVIII) 60123 (2E,4E,7S,8E)-7-{[tert-butyl(dimethyl)silyl]oxy}-9-iodo-8-methyl-2,4,8-nonatrienal C16H27IO2Si 详情 详情
(XXIX) 60124 (2R,4S,5S,6E,8E,11S,12E)-1-[(4S)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-11-{[tert-butyl(dimethyl)silyl]oxy}-5-hydroxy-13-iodo-4,12-dimethyl-2-[2-(2-methyl-1,3-dithian-2-yl)ethyl]-6,8,12-tridecatriene-1,3-dione C38H56INO6S2Si 详情 详情
(XXX) 60125 (4S)-4-benzyl-3-{(2R,3R,4S,5S,6E,8E,11S,12E)-11-{[tert-butyl(dimethyl)silyl]oxy}-3,5-dihydroxy-13-iodo-4,12-dimethyl-2-[2-(2-methyl-1,3-dithian-2-yl)ethyl]-6,8,12-tridecatrienoyl}-1,3-oxazolidin-2-one C38H58INO6S2Si 详情 详情
(XXXI) 60126 (4S)-4-benzyl-3-{[(3S,4R,5R,6R)-3-((1E,3E,6S,7E)-6-{[tert-butyl(dimethyl)silyl]oxy}-8-iodo-7-methyl-1,3,7-octatrienyl)-1,4-dimethyl-2,9-dioxabicyclo[3.3.1]non-6-yl]carbonyl}-1,3-oxazolidin-2-one C35H50INO6Si 详情 详情
(XXXII) 60127 [(3S,4R,5S,6S)-3-((1E,3E,6S,7E)-6-{[tert-butyl(dimethyl)silyl]oxy}-8-iodo-7-methyl-1,3,7-octatrienyl)-1,4-dimethyl-2,9-dioxabicyclo[3.3.1]non-6-yl]methanol C25H43IO4Si 详情 详情
(XXXIII) 60128 (3S,4R,5R,6R)-3-((1E,3E,6S,7E)-6-{[tert-butyl(dimethyl)silyl]oxy}-8-iodo-7-methyl-1,3,7-octatrienyl)-1,4-dimethyl-2,9-dioxabicyclo[3.3.1]nonane-6-carboxylic acid C25H41IO5Si 详情 详情
(XXXIV) 60129 methyl (3S)-1-[(2S)-3-{3-[(tert-butoxycarbonyl)oxy]-1,3-cyclohexadien-1-yl}-2-({(2S)-2-[({(3S,4R,5R,6R)-3-[(1E,3E,6S,7E)-6-hydroxy-8-iodo-7-methyl-1,3,7-octatrienyl]-1,4-dimethyl-2,9-dioxabicyclo[3.3.1]non-6-yl}carbonyl)amino]-3-methylbutanoyl}amino)propanoyl]hexahydro-3-pyridazinecarboxylate C44H65IN4O11 详情 详情
(XXXV) 60130 tert-butyl 3-({(4R,7S,10S,16S,19S,25S,26R,27R)-19-[(E)-2-iodo-1-methylethenyl]-7-isopropyl-1,26-dimethyl-5,8,11,17-tetraoxo-18,28,29-trioxa-6,9,12,30-tetraazatetracyclo[23.3.1.1~12,16~.0~4,27~]triaconta-21,23-dien-10-yl}methyl)phenyl carbonate C43H59IN4O10 详情 详情
(XXXVI) 32450 (4R,7S,10S,16S,19S,25S,26R,27R)-10-(3-hydroxybenzyl)-19-[(E)-2-iodo-1-methylethenyl]-7-isopropyl-1,26-dimethyl-18,28,29-trioxa-6,9,12,30-tetraazatetracyclo[23.3.1.1(12,16).0(4,27)]triaconta-21,23-diene-5,8,11,17-tetrone; (4R,7S,10S,16S,19S,25S,26R,27R)-10-(3-hydroxybenzyl)-19-[(E)-2-iodo-1-methylethenyl]-7-isopropyl-1,26-dimethyl-18,28,29-trioxa-6,9,12,30-tetraazatetracyclo[23.3.1.1(12,16).0(4,27)]triaconta-21,23-diene-5,8,11,17-tetrone C38H51IN4O8 详情 详情
Extended Information